₩5,420.00 ($4.03)

-20.00 (-0.37%)

Weekly Expected Move ±2.9%

₩5103 ₩5261 ₩5420 ₩5579 ₩5737

KSC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 47 · ₩129.6B mcap · 9M float · 0.560% daily turnover

Revenue

$264.1B +10.7% ▲

5Y CAGR: +4.2%

Gross Profit

$100.0B +21.3% ▲

5Y CAGR: +13.8%

Operating Income

$3.5B -66.3% ▼

5Y CAGR: -9.1%

Net Income

$108M -97.7% ▼

5Y CAGR: -59.1%

EPS (Diluted)

$4.52 -97.7% ▼

5Y CAGR: -59.1%

EBITDA

$16.7B -22.6% ▼

5Y CAGR: -4.7%

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$170.7B	$196.3B	$216.4B	$238.6B	$264.1B
YoY Growth	-20.7%	+15.0%	+10.2%	+10.3%	+10.7%
Cost of Revenue	$135.3B	$151.8B	$153.3B	$156.1B	$164.1B
Gross Profit	$35.4B	$44.4B	$63.1B	$82.4B	$100.0B
Gross Margin	20.7%	22.6%	29.2%	34.5%	37.9%
R&D Expenses	$5.1B	$3.1B	$3.7B	$5.3B	$0
SG&A Expenses	$19.4B	$24.0B	$35.8B	$47.0B	$0
Operating Expenses	$42.0B	$43.0B	$57.5B	$72.0B	$96.5B
Operating Income	-$4.6B	$1.4B	$5.5B	$10.5B	$3.5B
Operating Margin	-2.7%	0.7%	2.6%	4.4%	1.3%
Interest Expense	$1.2B	$1.7B	$3.4B	$4.3B	$4.3B
Income Before Tax	-$9.9B	-$615M	$2.2B	$4.9B	$449M
Tax Expense	-$2.4B	-$1.2B	-$802M	$264M	$341M
Net Income	-$7.5B	$611M	$3.0B	$4.6B	$108M
Net Margin	-4.4%	0.3%	1.4%	1.9%	0.0%
EPS (Diluted)	$-313.52	$25.54	$124.42	$194.06	$4.52
EBITDA	$4.2B	$12.8B	$17.2B	$21.6B	$16.7B
Shares Outstanding	24M	24M	24M	24M	24M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$58.2B	$59.3B	$60.6B	$65.3B	$67.0B	$71.2B	$66.1B	$75.2B
Cost of Revenue	$38.1B	$35.8B	$38.7B	$38.4B	$42.4B	$45.1B	$40.0B	$48.0B
Gross Profit	$20.1B	$23.5B	$21.9B	$26.9B	$24.6B	$26.2B	$26.1B	$27.3B
Gross Margin	34.5%	39.6%	36.1%	41.2%	36.7%	36.7%	39.5%	36.3%
R&D Expenses	$0	$0	$4.9B	$4.4B	$4.5B	$4.5B	$5.8B	$0
SG&A Expenses	$17.0B	-$4.4B	$21.7B	$14.9B	$14.3B	$16.1B	$16.4B	$0
Operating Expenses	$17.0B	$20.5B	$21.7B	$24.5B	$24.1B	$25.6B	$25.4B	$26.3B
Operating Income	$3.2B	$3.0B	$121M	$2.4B	$474M	$516M	$713M	$930M
Operating Margin	5.4%	5.0%	0.2%	3.7%	0.7%	0.7%	1.1%	1.2%
Interest Expense	$1.3B	$803M	$1.4B	$742M	$1.2B	$1.5B	$1.7B	$1.8B
Income Before Tax	$1.4B	$1.3B	-$982M	-$1.0B	$3.4B	-$995M	-$742M	$4.3B
Tax Expense	$313M	-$448M	-$287M	$705M	$412M	-$488M	-$212M	$1.3B
Net Income	$1.1B	$1.8B	-$695M	-$1.7B	$3.0B	-$507M	-$530M	$3.0B
Net Margin	1.9%	3.0%	-1.1%	-2.7%	4.5%	-0.7%	-0.8%	4.0%
EPS (Diluted)	$45.22	$73.27	$-29.07	$-73.00	$127.00	$-21.20	$-22.17	$124.40
EBITDA	$6.3B	$4.8B	$3.3B	$5.7B	$3.9B	$4.0B	$4.3B	$4.6B
Shares Outstanding	24M	24M	24M	24M	24M	24M	24M	24M

214390.KS KSC